Patent ID: 8815519
Filing Date: 2014-08-26
Classification: G01N

Abstract:
1. A method for predicting the risk of developing a metabolic syndrome-related disease and/or low-grade inflammation-related disease in a mammalian subject, in particular, a human subject, comprising: (a) obtaining a sample of blood serum or blood plasmas from a subject to determine if the subject is at risk of developing a metabolic syndrome-related disease, and/or low-grade inflammation-related disease, (b) measuring in vitro the level of (i) soluble urokinase plasminogen activator receptor (suPAR) and (ii) D2D3 cleavage products of suPAR in the one or more samples of blood serum or blood plasma derived from said subject, using immunodetection, western blot, Luminex, MALDI-TOF, or HPLC, and (c) determining if the measured level of suPAR and D2D3 is greater than 4.029 ng/ml for the blood serum or blood plasma sample, which is indicative of an increased risk of developing a metabolic syndrome disease and/or low-grade inflammation disease, wherein said disease is cardiovascular disease.